Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet. The company also offers accessory and consumable products for bioprinting and single-cell biology. The company was incorporated in 2012 and is based in Mölndal, Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $0.00848855942721693 | N/A |
Market Cap | $993.52K | N/A |
Shares Outstanding | 117.04M | N/A |
Employees | 20.00 | N/A |